Author: Nichols Martin|| Date Published: September 28, 2018
The Food and Drug Administration has awarded four companies contracts worth up to $75M each to develop automated methods for reporting adverse drug events.
IBM (NYSE: IBM), Acumen, Dovel Technologiesand IQVIA Government Solutions will use artificial intelligence, machine learning, natural language processing and other automation techniques to create data collection and analysis systems for the FDA’s Center for Biologics Evaluation and Research, the agency said Thursday in a FedBizOpps notice.
FDA requires each contractor to offer indirect access to medical information of U.S. patients, including administrative and claims data and electronic health records.
The indefinite delivery/indefinite quantity contracts have a five-year ordering period.
The agency also selected the four companies to develop surveillance tools as part of the Biologics Effectiveness and Safety Initiative.
The Army Contracting Command-Aberdeen Proving Ground and the Capability Program Executive Enterprise Software and Service, formerly Program Executive Office Enterprise,…
LMI has been awarded a $100 million Small Business Innovation Research Phase III indefinite-delivery/indefinite-quantity contract to support life cycle logistics and…
Melissa Bischoping, senior director of security and product design research at Tanium, said adopting agentic artificial intelligence and other autonomous…
The Food and Drug Administration has awarded four companies contracts worth up to $75M each to develop automated methods for reporting adverse drug events.
